EGFR and non-small cell lung carcinoma: Therefore, whether immunotherapy combined with chemotherapy or anti-angiogenesis agent could be an effective option for EGFR-mutated NSCLC after exhaustion of targeted therapies is under research in ongoing KEYNOTE-789 (NCT03515837) and Checkmate-722 (NCT02864251) and ORIENT-31 (NCT03802240) studies.